AP NEWS

Strongbridge Biopharma plc to Participate in Two Upcoming Healthcare Investor Conferences

September 18, 2018

DUBLIN, Ireland and TREVOSE, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the Company will participate in two upcoming healthcare investor conferences. The details are as follows:

Oppenheimer Fall Summit - Focused on Specialty Pharma and Rare Disease Date: Wednesday, September 26, 2018 Management to host one-on-one investor meetings Location: The Langham, New York

2018 Cantor Global Healthcare Conference Date: Tuesday, October 2, 2018 Corporate presentation: 10:55a.m. ET Location: Intercontinental New York Barclay Hotel

The presentation at the 2018 Cantor Global Healthcare Conference will be webcast live and available on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

About Strongbridge BiopharmaStrongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes MACRILEN™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency, RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. MACRILEN has orphan drug exclusivity in the United States, and both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Contacts:

Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 lrocco@elixirhealthpr.com

Investor Relations

U.S.:Solebury Trout Marcy Nanus +1 646-378-2927 mnanus@soleburytrout.com

Europe:First HouseGeir Arne Drangeid +47 913 10 458 strongbridgebio@firsthouse.no Strongbridge Biopharma plc900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389

AP RADIO
Update hourly